DICE Therapeutics
new injectable data in clarifies role of subtype selectivity and tissue penetration | DICE Therapeutics
Company
Deck Type
Deck date
March 2023
Slide
27 of 28
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
September 2023
spy is a potentially best in class anti a with near term risking studies anticipated | Aeglea BioTherapeutics
Aeglea BioTherapeutics
Investor Presentation
September 2023
spy is a potentially best in class anti a with near term risking studies anticipated as | Aeglea BioTherapeutics
Aeglea BioTherapeutics
Investor Presentation
July 2023
spy is a potentially best in class anti a with near term risking studies anticipated on | Aeglea BioTherapeutics
Aeglea BioTherapeutics
Mergers and Acquisitions
June 2023
spy is a potentially best in class anti a with near term risking studies anticipated as | Aeglea BioTherapeutics
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io